Incidence and characteristics of kidney stones in patients with horseshoe kidney: A systematic review and meta-analysis

Aditya S. Pawar, Charat Thongprayoon, Wisit Cheungpasitporn, Ankit Sakhuja, Michael A. Mao, Stephen B. Erickson

Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, Department of Internal Medicine, Bassett Medical Center, Cooperstown, NY, USA

Abstract

Introduction: The horseshoe kidney (HSK) is the most common type of renal fusion anomaly. The incidence and characteristics of kidney stones in patients with HSK are not well studied. The aim of this meta-analysis was to evaluate the incidence and types of kidney stones in patients with HSK.

Methods: A systematic literature search was performed using MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews from the databases’ inception through November 2016. Studies assessing the incidence and types of kidney stones in patients with HSK were included. We applied a random-effects model to estimate the incidence of kidney stones. The study protocol was registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42016052037).

Results: A total of 14 observational studies with 943 patients (522 adults and 421 pediatric) with HSK were enrolled. The estimated pooled incidence of kidney stones was 36% (95% confidence interval [CI], 15%–59%) in adults with the HSK. Kidney stones were less common in pediatric patients with HSK with an estimated pooled incidence of 3% (95% CI, 2%–5%). The mean age of adult stone formers with HSK was 44.9 ± 6.2 years, and 75% were males. Within reported studies, 89.2% of kidney stones were calcium-based stones (64.2% calcium oxalate [CaOx], 18.8% calcium phosphate [CaP], and 6.2% mixed CaOx/CaP), followed by struvite stones (4.2%), uric acid stones (3.8%), and others (2.8%).

Conclusions: Kidney stones are very common in adult patients with HSK with an estimated incidence of 36%. Calcium-based stones are the most prevalent kidney stones in adults with HSKs. These findings may impact the prevention and clinical management of kidney stones in patients with HSK.

Keywords: Horseshoe kidney, incidence, kidney stones, nephrolithiasis

INTRODUCTION

Kidney stone disease, also known as nephrolithiasis, is a common problem worldwide, with a prevalence of 7% in the adults, and ≥30% recurrence rate within 10 years. The incidence of kidney stones is globally increasing with an estimated prevalence ranging up to 15%. During
Horseshoe kidney (HSK) is the most common abnormality renal fusion anomaly,[13] estimated to be 1/400–1600 births with the prevalence of 0.25% among the general population.[14-16] Its developmental abnormalities include the fusion of the lower poles, resulting in abnormal position of the ureter in the renal pelvis, and highly placed ureteropelvic junction.[17] Impaired drainage of the collecting system and associating ureteropelvic obstruction may predispose the patient to kidney stones.[14,18-22] Besides, metabolic factors have also been suggested to contribute to stone in patients with HSK.[15,18,23-25] Nevertheless, unlike the general population, the incidence and characteristics of kidney stones in patients with HSK are not well examined. The objective of this meta-analysis was to evaluate the incidence and types of kidney stones in patients with HSK.

EVIDENCE ACQUISITION

Search strategy
The protocol for this study is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42016052037). We also followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.[26] Two investigators (ASP and CT) systematically reviewed the published literature and conference abstracts indexed in MEDLINE, EMBASE, and the Cochrane Databases from database inception through November 2016 without language restrictions, using the terms: “stone” or “nephrolithiasis” combined with “kidney” and “horseshoe”. Other pertinent references were obtained through manual review of these retrieved references.

Inclusion criteria and outcomes
The inclusion criteria were (1) randomized controlled trials (RCTs) or observational studies (case–control, cross-sectional, cohort studies, or case series), (2) both adults and pediatric patient populations with HSK, and (3) data on kidney stones in patients with HSK were provided. Both published studies and conference abstracts were included. Study eligibility was independently determined by the two investigators mentioned earlier. Differing decisions were resolved by joint agreement.

Data extraction
A standardized information collection form was utilized to obtain the resulting data: the first author, study design, year of publication, country where the study was conveyed, number of patients with HSK kidney studied, number of HSK kidney patients with kidney stones, age and gender of patients with HSK, time of diagnosis of kidney stones, type and location of kidney stones, urine supersaturation profiles, treatment of kidney stones, and outcomes of patients with HSK with kidney stones.

Statistical analysis
MetaXL software (EpiGear International Pty. Ltd., Queensland, Australia)[27] was utilized for data analysis. The incidence rates and 95% confidence intervals (CIs) of adverse effects were reported using a DerSimonian–Laird random-effects model.[28] As per our study protocol, a prespecified analysis by adult and pediatric population was performed. A random-effects model was implemented due to the high likelihood of interstudy variances. The Cochran Q-test was completed to appraise statistical heterogeneity. The $I^2$ statistic was added to evaluate the degree of variation across studies related to heterogeneity instead of chance. An $I^2$ of 0%–25% represents insignificant heterogeneity, 26%–50% low heterogeneity, 51%–75% moderate heterogeneity, and >75% high heterogeneity.[29] To assess for publication bias funnel plots were utilized.[30]

RESULTS

Our search strategy yielded 655 articles. Of these, 607 articles were excluded following the review of their title and abstract based on their relevance and the eligibility criteria. The remaining 48 articles underwent full-length review, and an additional 34 were excluded for failing to meet the criteria (23 articles were excluded because they did not report the outcomes of interest and 11 articles were excluded because they were not observational studies or RCTs).

Fourteen observational studies[14,15,18-22,24,31-37] with 943 patients (522 adults and 421 pediatric) with HSK met all inclusion criteria and were enrolled for this systematic review and meta-analysis of kidney stones in patients with HSK [Tables 1 and 2]. Figure 1 outlines our search methodology and selection process.

Incidence of kidney stones in patients with horseshoe kidney
Six studies[14,18-22] evaluated the incidence of kidney stones in patients with HSK as demonstrated in Table 1. The estimated pooled incidence of kidney stones was 36% [95% CI, 15%–59%, $F = 88%$; Figure 2] in adults with HSK. The mean age of adult stone formers with HSK...
Table 1: Main characteristics of the observational studies included in the meta-analysis of incidence of stone incidence

| Country       | Year | Total number HSK patients | Number of patients with kidney stones | Sex of HK patients | Age of HK patients (years) | Stone location | Stone composition | Urine supersaturation | Size of stones and treatment | Outcomes |
|---------------|------|---------------------------|--------------------------------------|-------------------|---------------------------|----------------|------------------|----------------------|--------------------------|----------|
| USA           | 1981 | 43                        | 10                                   | NR                | 42.7 years (range 0-67)   | 6 kidney; 3 ureter | 8 stones analyzed; 3 CaOx, 1 CaP, 2 MgP (infectious), 1 matrix, 1 unknown | Metabolic abnormality evaluation: 6/8 (75%) had metabolic abnormalities; 4 had hypercalciuria | NR         | See below |
| USA           | 2003 | 23                        | 9                                    | NR                | NR                        | NR             | 5 of 9 CaOx stone composition | Metabolic abnormality evaluation: 4 (44.4%); low urinary volume, 2 hypocitruria, 3 hypercalciuria, 2 hyperuricosuria, 1 hyperoxaluria, 2 calcium oxalate stone composition | NR         |
| Thailand      | 2012 | 14                        | NR                                   | 16 (69.6%) males, 7 (30.4%) females | 19-74 years (mean age 51.1 years) | NR             | NR               | 6/8 (75%) had metabolic abnormalities; 4 had hypercalciuria | 11 kidney; 4 ureter | NR       |
| USA           | 2015 | 380                       | 11                                   | 12 were men and two were women | Median age, 2.8 years; range, 0-20 years; IQR, 9.7 years | NR             | NR               | NR                  | Average stone was 11.2 mm × 14 mm | Obstruction from stones occurred in 7 patients (77.8%). Conservative management was the preferred initial treatment choice for most stone cases in this group, followed by PNL |
| USA           | 2015 | 41                        | NR                                   | 15 males (62%) and | 60 (2-192) months | NR             | NR               | NR                  | NR          |
| Turkey        | 2015 | 41                        | NR                                   | 22 girls (53.6%) and 19 boys (46.4%) | NR             | NR               | NR                  | NR          |
| Saudi Arabia  | 2016 | 144                       | 25                                   | NR                | NR                        | NR             | NR               | NR                  | NR          |

CaOx: Calcium oxalate; CaP: Calcium phosphate; NR: Not reported, SWL: Shock wave lithotripsy, PNL: Percutaneous nephrolithotomy, HSK: Horseshoe kidney, MgP: Matrix gla protein, IQR: Interquartile range
was 44.9 ± 6.2 years, and 75% were males. Kidney stones were less common in pediatric patients with HSK with an estimated pooled incidence of 3% (95% CI, 2%–5%, \( I^2 = 0\% \)).

Geographic information was provided in Table 1; 3 studies from the United States and 2 studies from Western Asia and a study from Southeast Asia. Overall, there were no racial preferences. The estimated incidences of kidney stones in adult patients with HSK was 30% (95% CI, 15%–46%; \( I^2 = 43\% \)) in the United States. Data on the incidence of kidney stones in patients with HSK in other geographical area were limited. The incidence of kidney stones in adult patients with HSK in Asia ranged between 17% and 79%.

Types and locations of kidney stones in patients with horseshoe kidney
Ten studies[14,15,18,24,31-37] assessed the type of kidney stones in HSK stone formers as shown in Tables 1 and 2. About 89.2% of kidney stones were calcium-based stones (64.2% calcium oxalate [CaOx], 18.8% calcium phosphate [CaP], 6.2% mixed CaOx/CaP), followed by struvite stones (4.2%), uric acid stones (3.8%), and others (2.8%).

Risk factors for kidney stones in patients with horseshoe kidney
This may be owing to ureteropelvic junction obstruction and to the orientation of the calyces, which prevent the passage of the stones.[15,25,38] Metabolic factors have

---

### Table 2: Main characteristics of the observational studies with types of kidney stones in patients with horseshoe kidney

| Country       | Raj et al.[24,31] | Shokeir et al.[32] | Miller et al.[33] | Ray et al.[34] |
|---------------|------------------|--------------------|-------------------|--------------|
| Year          | USA              | Egypt              | USA               | Canada       |
| Total number of patients with HK | 37               | 34                 | 35                | 41           |
| Number of kidney stones analyzed | 24               | 20                 | 58                | 31           |
| 24 h urine studies | NR               | NR                 | All 16 patients had at least one abnormality (mean 2.94 per patient) with hypercalciuria (81.2%) and low urinary volume (68.8%) being the most commonly identified 29 men and 6 women | NR           |
| Sex of patients with stone | NR               | 30 were males and 4 were females | 25 men/6 female | NR           |
| No of stones with each patient single multiple | Multiple mostly (exact number not reported) | 41.6±10 | 55.4 (range 29-84) | 52.5±12.1 |
| Mean age (years) | 49.5 (range 29-76) | NR                 | 28.6% upper pole; 11.4% interpolar; 74.3% lower pole; 80% renal pelvis | NR           |
| Stone composition | 87.5% calcium, 71% CaOx monohydrate stones, 42% CaP, and 33% CaOx dihydrate | 50% CaOx, 20% struvite stones, 30% mixed stones | 26 calcium oxalate monohydrate, 4 calcium dihydrate, 1 CaP | NR           |

| Country       | Skolarikos et al.[35] | Wu et al.[36] | Ding et al.[37] | Blackburne et al.[38] |
|---------------|-------------------------|---------------|-----------------|-----------------------|
| Year          | Greece                  | China         | China           | USA                   |
| Total number of patients with HSK | 58               | 32             | 16              | 45                    |
| Number of kidney stone analyzed | 77               | 35             | 16              | 51                    |
| Sex of patients with stone | 47 men/11 female | 22 male, 10 female | 13 male, 3 female | 31 male, 14 female |
| Age of patients with stone | 39.9±13.6 | 38.2 (range 14-72) | 42.9±11.6 | 49.4 (range 23-78) |
| Stone location | NR                      | 6 staghorn, 9 semi-staghorn, 7 multiple, 6 pelvic, 3 lower pole, 1 interpolar region, 2 upper ureter, 1 semi-staghorn + upper ureter | 2 multiple, 9 pelvic, 5 lower pole | NR |
| Stone composition | 63.7% simple stone, 36.2% complex stone, 32.7% staghorn stone | (27/35, 77.1%) CaOx, (4/35, 11.5%) CaP, (2/35, 5.7%) uric acid, (2/35, 5.7%) struvite | 9 CaOx monohydrate, 5 CaOx dihydrate, 2 uric acid | 27 CaOx stones, 7 apatite, 4 brushite, 3 struvite, 6 uric acid, 3 mixed, 1 dihydroxy adenine |

CaOx: Calcium oxalate, CaP: Calcium phosphate, NR: Not reported, HSK: Horseshoe kidney
also been suggested to contribute to stone formation including hyperparathyroidism, low urine volumes, hypercalciuria, hyperoxaluria, hyperuricosuria, and hypocitraturia.\cite{15,18,23-25}

**Treatment and outcomes of kidney stones in patients with horseshoe kidney**

An HSK is formed by fusion across the midline of two distinct functioning kidneys, connecting at the lower poles by an isthmus, which may prevent the ascent of kidney stones.\cite{25} Although ureteroscopy (URS) and extracorporeal shock wave lithotripsy (ESWL) are less effective than percutaneous nephrolithotomy (PCNL) for the treatment of kidney stones in patients with HSK, studies have reported successful treatment with URS and/or ESWL, particularly in small (<15–20 mm) calculi.\cite{15,22} PCNL was used for large stones and required one to four stages to achieve an overall stone clearance rate of >80%.\cite{25}

**Evaluation for publication bias**

A funnel plot was not drawn because of the limited number of studies. As a rule of thumb, tests for funnel plot asymmetry should be used only when there are at least ten study groups. Due to limited number of included studies evaluating the incidence of kidney stones in patients with HSK, the power of the test is too low to distinguish chance from real asymmetry.\cite{39}

**DISCUSSION**

In this study, we showed that an overall incidence of kidney stones in adults with HSK was 36%. Kidney stones were less common in pediatric patients with HSK with an estimated incidence of 3%. The mean age of adult stone formers with HSK was 45 years, and 75% were males. Calcium-based (CaOx and CaP) stones were the most prevalent types of kidney stones in patients with HSK.

The incidence of kidney stones in patients with MSK from our meta-analysis is much higher than reported in the general adult populations.\cite{10-12} There are several plausible explanations. First, HSK-related abnormal position of the ureter in the renal pelvis and highly placed ureteropelvic junction\cite{17} can result in impaired drainage of the collecting system and predispose HSK patient to kidney stones.\cite{14,18-22} Second, previous studies have demonstrated that metabolic factors including hyperparathyroidism, low urine volumes, hypercalciuria, hyperoxaluria, hyperuricosuria, and hypocitraturia\cite{15,18,23-25} are common in patients with HSK, which may contribute to higher stone formation. Third, the previous reports have demonstrated coexistent HSK with medullary sponge kidney,\cite{40-42} a known cause of stone disease.\cite{43}

To date, there have been no available clinical trials comparing the treatment efficacy of URS, ESWL, or PCNL on kidney stones in patients with HSK. PCNL is generally recommended due to anatomical abnormalities and is used for large stones with stone clearance rate of >80%.\cite{25} However, studies have also shown that URS and ESWL may be effective in small stones.\cite{15,22}

There are several limitations to our study. First, there were statistical heterogeneities in the analysis of the incidence
of kidney stones in adult HSK patients. The potential sources of this heterogeneity included differences in diagnostic methodology of kidney stones. Second, most included studies were conducted in the United States with the majority of the participants being Caucasian. Therefore, the findings from our study may not represent HSK populations from other parts of the world, and the future studies are required.

CONCLUSIONS

Our meta-analysis demonstrates that kidney stones are common in patients with HSK with estimated incidence of 36%. Kidney stones are prevalent in males with HSK. Calcium-based stones were the most common types of kidney stones in patients with HSK.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Rule AD, Lieske JC, Li X, Melton LJ III, Krambeck AE, Bergstralh EJ. The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol 2014;25:2878-86.
2. Cheungpasitporn W, Thongprayoon C, Mao MA, O’Corragain OA, Edmonds PJ, Erickson SB. The risk of coronary heart disease in patients with kidney stones: A systematic review and meta-analysis. N Am J Med Sci 2014;6:580-5.
3. Lieske JC, Peña de la Vega LS, Slezak JM, Bergstralh EJ, Leibson CL, Ho KL, et al. Renal stone epidemiology in Rochester, Minnesota: An update. Kidney Int 2006;69:760-4.
4. Cheungpasitporn W, Erickson SB, Rule AD, Enders F, Lieske JC. Short-term tolvaptan increases water intake and effectively decreases urinary calcium oxalate, calcium phosphate and uric acid supersaturations. J Urol 2016;195:1476-81.
5. Cheungpasitporn W, Thongprayoon C, Mao MA, Kittanamongkolchai W, Jaffer Sathick IJ, Dhondup T, et al. Incidence of kidney stones in kidney transplant recipients: A systematic review and meta-analysis. World J Transplant 2016;24:6790-797.
6. Thongprayoon C, Cheungpasitporn W, Vijayvargiya P, Anantham P, Erickson SB. The risk of kidney stones following bariatric surgery: A systematic review and meta-analysis. Ren Fail 2016;38:424-30.
7. Cheungpasitporn W, Rossettì S, Friend K, Erickson SB, Lieske JC. Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: A systematic review and meta-analysis. J Nephrol 2016;29:211-9.
8. Cheungpasitporn W, Thongprayoon C, O’Corragain OA, Edmonds PJ, Ungprasert P, Kittanamongkolchai W, et al. The risk of kidney cancer in patients with kidney stones: A systematic review and meta-analysis. QJM 2015;108:205-12.
9. Shah J, Whitfield FN. Urolithiasis through the ages. BJU Int 2002;89:801-10.
10. Long IO, Park S. Update on nephrolithiasis management. Minerva Urol Nefrol 2007;59:317-25.
11. López M, Hoppe B. History, epidemiology and regional diversities of urolithiasis. Pediatr Nephrol 2010;25:49-59.
12. Stamatakou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003;63:1817-23.
13. Dhillon J, Mohanty SK, Kim T, Sexton WJ, Powsang J, Spisec PE. Spectrum of renal pathology in adult patients with congenital renal anomalies—a series from a tertiary cancer center. Ann Diagn Pathol 2014;18:14-7.
14. Weizer AZ, Silverstein AD, Auge BK, Delvecchio FC, Raj G, Alhala DM, et al. Determining the incidence of horseshoe kidney from radiographic data at a single institution. J Urol 2003;170:1722-6.
15. Ding J, Huang Y, Gu S, Chen Y, Peng J, Bai Q, et al. Flexible ureteroscopic management of horseshoe kidney renal calculi. Int Braz J Urol 2015;41:683-9.
16. Obidike S, Woha A, Aftab F. Fused ureters in patient with horseshoe kidney and aortic abdominal aneurysm. J Surg Case Rep 2014;2014:1-3.
17. Ntissi KI, Plagkou M, Skotsimara A, Protegerou V, Tsitouridis I, Skandalakis P. Horseshoe kidney: A review of anatomy and pathology. Surg Radiol Anat 2014;36:517-26.
18. Evans WP, Resnick MI. Horseshoe kidney and urolithiasis. J Urol 1981;125:620-1.
19. Muttarak M, Sriburi T. Congenital renal anomalies detected in adulthood. Biomed Imaging Interv J 2012;8:e7.
20. Je BK, Kim HK, Horn PS. Incidence and spectrum of renal complications and extrarenal diseases and syndromes in 380 children and young adults with horseshoe kidney. AJR Am J Roentgenol 2015;205:1306-14.
21. Yayue S, Kiyak A, Sander S. Renal outcome of children with horseshoe kidney: A single-center experience. Urology 2015;85:463-6.
22. Otyay AA, Sarhan O, Helaly AA, Alhedaiwi K, Ghanbar MA, Nakshabandi Z, et al. Different management options for horseshoe kidney stones: Single center experience. J Urol 2016;1:325.
23. Mottola A, Selli C, Carini M, Natali A. Lithiasis in horseshoe kidney. Acta Urol Belg 1984;52:355-60.
24. Raj GV, Auge BK, Assimos D, Preminger GM. Metabolic abnormalities associated with renal calculi in patients with horseshoe kidneys. J Endourol 2004;18:157-61.
25. Symons SJ, Ramachandran A, Kurien A, Bajysha R, Desai MR. Urolithiasis in the horseshoe kidney: A single-centre experience. BJU Int 2008;102:1676-80.
26. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-analyses: The PRISMA statement. Ann Intern Med 2009;151:264-9, W64.
27. Barnagred J, Doi S. MetaXL User Guide. Ver. 1.0. Wilston, Australia: Epigear International Pty. Ltd.; 2010.
28. DeSimmonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: An update. Contemp Clin Trials 2007;28:105-14.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
30. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991;337:867-72.
31. Raj GV, Auge BK, Weizer AZ, Deensteld JD, Watterson JD, Beiko DT, et al. Percutaneous management of calculi within horseshoe kidneys. J Urol 2003;170:48-51.
32. Shokir AA, El-Nahas AR, Shoma AM, Eraky I, El-Kenawy M, Mokhtar A, et al. Percutaneous nephrolithotomy in treatment of large stones within horseshoe kidneys. Urology 2004;64:426-9.
33. Miller NL, Matlaga BR, Handa SE, Munch LC, Lingeman JE. The presence of horseshoe kidney does not affect the outcome of percutaneous nephrolithotomy. J Endourol 2008;22:1219-25.
34. Ray AA, Ghiculetă D, D’A Honey RJ, Pace KT. Shockwave lithotripsy in patients with horseshoe kidney: Determinants of success. J Endourol 2011;25:487-93.
35. Skolarikos A, Binbay M, Bisas A, Sari E, Boardounis A, Tefekli A, et al. Percutaneous nephrolithotomy in horseshoe kidneys: Factors affecting stone-free rate. J Urol 2011;186:1894-8.
36. Wu W, Zhao Z, Zhu H, Yang D, Ou L, Liang Y, et al. Safety and efficacy of minimally invasive percutaneous nephrolithotomy in treatment of calculi in horseshoe kidneys. J Endourol 2014;28:926-9.

37. Blackburne AT, Rivera ME, GETTMAN MT, Patterson DE, Krambeck AE. Endoscopic Management of Urolithiasis in the Horseshoe Kidney. Urology 2016;90:45-9.

38. Schiappacasse G, Aguirre J, Soffia P, Silva CS, Zilleruelo N. CT findings of the main pathological conditions associated with horseshoe kidneys. Br J Radiol 2015;88:20140456.

39. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.

40. Irisawa C, Yamaguchi O, Shiraiwa Y, Kikuchi Y, Irisawa S, Irisawa C. A case of medullary sponge disease associated with horseshoe kidney. Nihon Hinyokika Gakkai Zasshi 1990;81:1255-7.

41. Lambrianides AI, John DR. Medullary sponge disease in horseshoe kidney. Urology 1987;29:426-7.

42. Cheungpasitporn W, Pawar AS, Erickson SB. Recurrent renal calculi in coexistence of horseshoe kidney and medullary sponge kidney. Urol Ann 2017;9:214-5.

43. Cheungpasitporn W, Thongprayoon C, Brabec BA, Kitanamongkolchai W, Erickson SB. Outcomes of living kidney donors with medullary sponge kidney. Clin Kidney J 2016;9:866-70.